Wound Care Biologics Market Expected to Reach $3.3 Billion by 2032—Allied Market Research

According to a new report published by Allied Market Research, titled, “Wound Care Biologics Market," The wound care biologics market size was valued at $1.8 billion in 2022, and is estimated to reach $3.3 billion by 2032, growing at a CAGR of 6.1% from 2023 to 2032. Wound care biologics are bioengineered products derived from natural sources that are used to treat and heal infections. Wound healing is a complex process that involves various disruptions in the tissue and skin layers.  

The wound care biologics market trends is driven by the factors such as the rise in cases of chronic wounds, technological advancements in biologics, rise in awareness of advanced wound care techniques, and surge in number of diabetic foot ulcer cases. The increase in prevalence of chronic wounds, such as diabetic foot ulcers and venous leg ulcers, is a major driving factor for the wound biologics market. Factors that contribute to this prevalence include the surge in aging population, the rise in chronic conditions such as diabetes and obesity, and lifestyle factors.   

Chronic wounds require advanced wound care solutions, and wound care biologics offer effective treatment options to promote healing in these complex cases. For instance, according to Centers for Disease Control and Prevention (CDC), 2022, about 12% people with diabetes develop diabetic foot ulcers in the U.S. Thus, rise in number of people suffering from diabetic foot ulcer drives the demand for effective treatment options and thereby, propels the growth of the wound biologics market.  

In addition, patients and healthcare providers seek innovative therapies, wound dressings, and basic wound care approaches fuels the wound care biologics market share. The demand for advanced wound healing technologies, including biologics, is driven by the desire for faster healing, reduced hospital stays, and improved patient satisfaction. Biologics offer the potential to accelerate the healing process and provide targeted and personalized treatments.   

Furthermore, continuous advancements in biotechnology and tissue engineering have led to the development of advanced biological skin substitutes and proples the wound care biologics market share. These products have incorporated innovative materials, growth factors, and cell-based technologies, enhancing their effectiveness in wound healing. The advancements make biological skin substitutes more appealing to healthcare providers and contribute to market growth. For instance, Triad Life Sciences, LLC, a part of Convatec company, manufactured InnovaMatrix AC, which is designed to address acute, traumatic, and hard-to-heal wounds. In addition, this product is manufactured with proprietary TriCleanse Placental Extracellular Matrix (ECM) process, offering benefits such as high-quality control, reliability, and safety profile of a medical device. Such advancements in wound care boost the wound biologics market growth.  

The wound care biologics industry is segmented into product, wound type, end user, distribution channel, and region. On the basis of product, the wound biologics market is bifurcated into biological skin substitutes and topical agents. The biological skin substitutes segment further classified into human donor tissue derived products, animal derived products, and cell based bioengineered products. The biological skin substitute segment dominated market share in 2022 and is also expected to register the highest CAGR during the forecast period, owing to effective wound healing properties of biological skin substitutes that make them a preferred choice for various wound types, including chronic wounds, burns, and surgical wounds.  

On the basis of wound type, the wound care biologics market size is categorized into acute wound and chronic wound. The acute wound segment is further classified into burns and trauma, and surgical. The chronic wound segment is further divided into pressure ulcer, diabetic ulcer, venous ulcer, and others. The chronic wound segment accounted for the largest share in 2022 and is expected to remain dominant during the forecast period owing to rise in prevalence of postoperative surgical wounds and surge in geriatric population suffering from chronic wound. In addition, rise in awareness toward advanced wound care and improved diagnosis and technological advancements in wound care products are expected to offer remunerative opportunities for market expansion.   

On the basis of end user, the wound care biologics market analysis is categorized into hospitals and clinics, wound centers and burn centers, and others. The hospitals and clinics segment occupied the largest share in 2022 owing to specialized wound care departments or dedicated wound care centers in hospitals that offer comprehensive treatment options for patients with complex or chronic wounds. These facilities are equipped with advanced infrastructure, specialized healthcare professionals, and the necessary resources to administer wound care biologics effectively, which support the wound care biologics industry growth.   

Region wise, North America is dominated the wound care biologics market, in terms of revenue owing to availability of well-developed infrastructure, presence of major key players, rise in prevalence of chronic diseases, and availability of trained medical professionals. In addition, the increase in sports injuries & road accidents and rise in prevalence of chronic wounds in the region foster the demand for wound care biologics products for road accidents & sports injuries.  

However, Asia-Pacific is anticipated to register the highest CAGR during wound care biologics market forecast period, owing to increase in cases of burns, trauma along with expanding healthcare infrastructure and increase in number of cases of chronic diseases, especially diabetes, which are projected to drive the growth of the wound care biologics market in emerging countries in Asia-Pacific.  

Key Findings of the Study  

• On the basis of product, the biological skin substitutes segment was largest contributor to the market in 2022.  
• On the basis of wound type, the chronic wound segment was largest contributor to the market in 2022.  
• On the basis of end user, the hospitals and clinics segment dominated the market in terms of revenue in 2022.   
• Region wise, North America generated the largest revenue in 2022. However, Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period.